Update on treatment options for newly diagnosed ovarian cancer

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 10, 2010, Pages 675-678

  Armstrong, Deborah ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AMG 386; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EC 145; FARLETUZUMAB; MORPHOTEK; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG TARGETING; EPITHELIUM CELL; GENE MUTATION; GENETIC PREDISPOSITION; GERM CELL; HEALTH CARE ACCESS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LUNG CANCER; MUTATIONAL ANALYSIS; OVARY CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STROMA CELL; TRANSVAGINAL ECHOGRAPHY; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASS SCREENING; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS;

EID: 78649918804     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010; 28(15s):Abstract 3002.
2. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010; 28(15s):Abstract LBA1.
3. White AJ, Coleman RL, Armstrong DK, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010; 28(15s):Abstract 5001.
4. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943-953.